Name | AZD1656 |
---|---|
Synonyms |
660M185X4D
3-{[5-(1-Azetidinylcarbonyl)-2-pyrazinyl]oxy}-5-{[(2S)-1-methoxy-2-propanyl]oxy}-N-(5-methyl-2-pyrazinyl)benzamide AZD1656 Benzamide, 3-[[5-(1-azetidinylcarbonyl)-2-pyrazinyl]oxy]-5-[(1S)-2-methoxy-1-methylethoxy]-N-(5-methyl-2-pyrazinyl)- |
Description | AZD1656 is a potent, selective and orally active glucokinase activator with an EC50 of 60 nM. AZD1656 has the potential for type 2 diabetes research[1][2][3]. |
---|---|
Related Catalog | |
Target |
EC50: 60 nM (Glucokinase)[2] |
In Vivo | AZD1656 (0-9 mg/kg; oral gavage; daily; for 8 weeks; C57BL/6 mice) treatment shows lowered blood glucose and glucose excursion and raised insulin. Liver mRNA levels for various ChREBP target genes including carbohydrate response element binding protein beta isoform (ChREBP-β), G6pc, Pklr, Acly, Acac and Gpd2 are increased by AZD1656[1]. Animal Model: C57BL/6 mice[1] Dosage: 0 mg/kg, 2 mg/kg, 4.5 mg/kg, 9 mg/kg Administration: Oral gavage; daily; for 8 weeks Result: Administered 2 hours before the oral glucose tolerance test, lowered blood glucose and glucose excursion and raised insulin. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 635.0±55.0 °C at 760 mmHg |
Molecular Formula | C24H26N6O5 |
Molecular Weight | 478.500 |
Flash Point | 337.8±31.5 °C |
Exact Mass | 478.196472 |
LogP | -0.21 |
Vapour Pressure | 0.0±1.9 mmHg at 25°C |
Index of Refraction | 1.631 |
Storage condition | -20℃ |